^
    Back
    Association details:
    Biomarker:IDH1 mutation
    Cancer:Glioma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet Oncol
    Title:

    Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

    Published date:
    05/14/2021
    Excerpt:
    Median follow-up was 55·7 months (IQR 41·0–77·3)….adjuvant temozolomide improved overall survival compared with no adjuvant temozolomide (median overall survival 82·3 months [95% CI 67·2–116·6] vs 46·9 months [37·9–56·9]; HR 0·64 [95% CI 0·52–0·79], p<0·0001)....Clinical benefit was dependent on IDH1 and IDH2 mutational status.
    DOI:
    https://doi.org/10.1016/S1470-2045(21)00090-5
    Trial ID:
    CATNON
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma

    Excerpt:
    ...- Anaplastic Oligodendroglioma without IDH1 mutation and...
    Trial ID:
    NCT02099487
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of Olutasidenib and Temozolomide in HGG

    Excerpt:
    ...Establish the RP2D of Olutasidenib and Temozolomide (Feasibility cohort)`Assess Progression-Free Survival (PFS) in Grade 3 IDH1-mutant Astrocytoma (Stratum A)`Maximum plasma concentration [Cmax] of Olutasidenib...
    Trial ID:
    NCT06161974
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A study of experimental drug NMS-03305293 in combination with temozolomide in adult patients with a type of brain tumour called glioblastoma

    Excerpt:
    ...Se l'IHC viene eseguito ed è negativo, e il paziente ha < 55 anni, è necessario eseguire il sequenziamento o un test convalidato basato sulla PCR per escludere altre mutazioni IDH1 o IDH2 più frequenti.4. ...
    Trial ID:
    2020-003417-35
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res Treat
    Title:

    Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma

    Published date:
    10/13/2020
    Excerpt:
    ...we confirmed that gliomas with IDH1 mutation were more sensitive to TMZ in vivo compared to wild type significantly and the results were consistent with the in vitro experiment.
    DOI:
    10.4143/crt.2020.506